MannKind Corp. Stock
Price
Target price
€3.90
€3.90
-1.940%
-0.076
-1.940%
€6.42
25.04.24 / Tradegate
WKN: A2DMZL / Symbol: MNKD / Name: MannKind / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
MannKind Corp. Stock
A loss of -1.940% shows a downward development for MannKind Corp..
MannKind Corp. is currently one of the favorites of our community with 7 Buy predictions and no Sell predictions.
As a result the target price of 6 € shows a very positive potential of 53.81% compared to the current price of 3.9 € for MannKind Corp..
Pros and Cons of MannKind Corp. in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of MannKind Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| MannKind Corp. | -1.940% | 1.641% | -13.618% | 8.936% | 15.757% | 0.958% | 174.139% |
| Ardelyx Inc. | -2.390% | -2.578% | -17.883% | 40.048% | 2.007% | -13.927% | - |
| Salarius Pharmaceuticals Inc. | -3.170% | -2.727% | -46.500% | -69.209% | -22.883% | -98.244% | -99.994% |
| Brainstorm Cell | 1.170% | 3.754% | -21.032% | -81.975% | 114.440% | -80.717% | - |
Comments
MannKind Co. (NASDAQ: MNKD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $6.50 price target on the stock.
Show more
Ratings data for MNKD provided by MarketBeat
MannKind Co. (NASDAQ: MNKD) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $10.00 price target on the stock.
Show more
Ratings data for MNKD provided by MarketBeat
MannKind Co. (NASDAQ: MNKD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $6.50 price target on the stock.
Show more
Ratings data for MNKD provided by MarketBeat
News
MannKind (MNKD) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
MannKind (NASDAQ: MNKD)Q4 2023 Earnings CallFeb 27, 2024, 5:00 p.m. ET
Operator
Source Fool.com
MannKind (MNKD) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
MannKind (NASDAQ: MNKD)Q3 2023 Earnings CallNov 07, 2023, 5:00 p.m. ET
Operator
Source Fool.com